Edmond DE Rothschild Holding S.A. trimmed its stake in Novo Nordisk A/S (NYSE:NVO) by 18.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,731 shares of the company’s stock after selling 3,531 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in Novo Nordisk A/S were worth $675,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Proficio Capital Partners LLC grew its stake in Novo Nordisk A/S by 155.6% during the 1st quarter. Proficio Capital Partners LLC now owns 2,472 shares of the company’s stock worth $103,000 after buying an additional 1,505 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Novo Nordisk A/S by 167.8% during the 1st quarter. Tower Research Capital LLC TRC now owns 3,061 shares of the company’s stock worth $105,000 after buying an additional 1,918 shares during the last quarter. AlphaMark Advisors LLC grew its stake in Novo Nordisk A/S by 1.1% during the 2nd quarter. AlphaMark Advisors LLC now owns 2,645 shares of the company’s stock worth $113,000 after buying an additional 30 shares during the last quarter. Parallel Advisors LLC grew its stake in Novo Nordisk A/S by 120.3% during the 1st quarter. Parallel Advisors LLC now owns 2,844 shares of the company’s stock worth $117,000 after buying an additional 1,553 shares during the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC grew its stake in Novo Nordisk A/S by 3,609.0% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,709 shares of the company’s stock worth $127,000 after buying an additional 3,609 shares during the last quarter. 6.01% of the stock is owned by hedge funds and other institutional investors.
Novo Nordisk A/S (NYSE NVO) opened at 48.67 on Tuesday. The stock has a market capitalization of $120.71 billion, a P/E ratio of 19.66 and a beta of 0.60. The company’s 50-day moving average price is $45.79 and its 200 day moving average price is $41.03. Novo Nordisk A/S has a 52 week low of $30.89 and a 52 week high of $48.88.
The company also recently announced an annual dividend, which was paid on Tuesday, August 29th. Stockholders of record on Monday, August 21st were given a dividend of $0.336 per share. The ex-dividend date of this dividend was Friday, August 18th. This represents a dividend yield of 1.07%. This is a boost from Novo Nordisk A/S’s previous annual dividend of $0.33. Novo Nordisk A/S’s payout ratio is 36.44%.
Several research analysts recently weighed in on the company. Zacks Investment Research downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday. Bank of America Corporation upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, September 6th. Finally, BidaskClub upgraded Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $55.00.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.